Compare Natera Inc. Common Stock (NTRA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Standard Lithium Ltd — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Standard Lithium Ltd trades at $1.41 (market cap $354.24M). The key difference: Natera Inc. Common Stock is far larger — about 161× Standard Lithium Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Standard Lithium Ltd for 24 Days on average.
| NTRA | SLI | |
|---|---|---|
Market Cap | $57.03B | $354.24M |
Volume | 1,131,157 | 1,656,773 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $5.65 |
52-Week Low | $179.42 | $1.38 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $56.18B | $217.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Standard Lithium (SLI) trades at $1.43, down 4.03% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no current revenue, but has made significant progress on its Arkansas lithium project with recent offtake agreements and government support. Analyst consensus remains strongly bullish with 100% buy ratings and a $3.83 price target, representing 168% upside potential from current levels.
The investment case hinges on successful execution of the South West Arkansas project, which could begin production in 2029. Key risks include negative cash flow from operations, high capital requirements, and project timeline delays. The stock offers speculative upside if the company can transition from development to production phase successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
